# Guanghua Wutong Fund

> Guanghua Wutong Fund is a VC fund backing Medical and Health Care. See 14 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 14
- Last investment: Jul 2026
- Lead investor: 7%
- Last updated: Aug 2026

Guanghua Wutong Fund is an investment fund.

## Contacts

5 contacts available for Guanghua Wutong Fund. Shizune tracks 2 team members at Guanghua Wutong Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/guanghua-wutong-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 5 | 36% |
| Health Care | 5 | 36% |
| Medical Device | 4 | 29% |
| Biotechnology | 3 | 21% |
| Pharmaceutical | 2 | 14% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 43% |
| Series A | 4 | 29% |
| Venture - Series Unknown | 2 | 14% |
| Seed | 1 | 7% |
| Debt Financing | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 10 | 71% |
| United States | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Deng Yixin | Vice President | 1 | https://shizune.co/investors/profile/deng-yixin |
| Xiang Wentian | Managing Director | 4 | https://shizune.co/investors/profile/xiang-wentian |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tianneng Jingxiu | Tianneng Jingxiu is an AI-powered bio-breeding platform provider that focuses on providing comprehensive technical solutions for the innovation and creation of crop seeds, primarily engaged in the development of intelligent nuclear sterile seed production technology for maize. |  | Series A | Jul 13, 2026 |  |
| Hengyu Medical | Hengyu Medical is a medical device firm focused on R&D and production of IVUS and optical coherence tomography, and catheter equipment. | $14.1M | Venture - Series Unknown | Dec 08, 2025 |  |
| Brise Pharma | Brise Pharma operates in the scientific research and technical service industry. | $28.1M | Series A | Nov 11, 2025 |  |
| Suzhou Meichuang | Meichuang Medical is an innovative medical device company that focuses on the R&D, manufacturing and commercialization of high-end medical devices in the fields of peripheral vascular intervention, tumor intervention, and hemodialysis access maintenance | $27.8M | Series B | Jun 13, 2025 |  |
| RootPath | RootPath is a Cambridge-based biotechnology company developing a powerful personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. Their next generation technologies allow us to precisely monitor, modulate and steer the immune system for a revolution in the diagnosis and treatment of cancer. | $1.4M | Venture - Series Unknown | Apr 24, 2025 |  |
| Strongest Laser | Strongest Laser is a high-power fiber laser equipment developer. |  | Series B | Mar 31, 2025 |  |
| Rona Therapeutics | Rona Therapeutics is a RNA therapeutics platform enabling discovery and development of modular and programmable RNA medicines. | $25M | Series B | Mar 14, 2025 |  |
| Hexaell Biotech | Hexaell Biotechnology Co., Ltd is a start-up company pioneering in stem cell and artificial organ. The disruptive technologies were original published in "Nature. 475(7356):386-9" and "Cell Stem Cell. 14(3):370-84" from Chinese Academy of Sciences. Hexaell Biotechnology had licensed iHep and HiHep technologies from ChineseAcademy of Sciences and developed medical devices of bio-artificial liver to replace liver function of human and cure liver failure diseases. Hexaell has finished pilot clinical studies in 6 liver failure patients in leading hepatopathy centers in China. | $27.4M | Series B | Feb 08, 2025 |  |
| C Ray Therapeutics | C Ray Therapeutics develops healthcare advancements through nuclear medicine. It was founded in 2020. | $100M | Series A | Nov 16, 2024 |  |
| Qinglan Jichuang | Qinglan Jichuang is a domestic high-performance intelligent endoscope innovative enterprise. |  | Seed | Oct 28, 2024 |  |

10 of 14 investments shown.

## Co-investors
- [Chengdu Science and Technology Venture Capital](https://shizune.co/investors/profile/chengdu-science-and-technology-venture-capital-group) — VC Fund, 2 deals together
- [Chengwei Capital](https://shizune.co/investors/profile/chengwei-capital) — VC Fund, 2 deals together
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 2 deals together
- [Junson Capital](https://shizune.co/investors/profile/junson-capital) — VC Fund, 2 deals together
- [Prosperity7 Ventures](https://shizune.co/investors/profile/prosperity7-ventures-d527) — VC Fund, 2 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Guanghua Wutong Fund invest in?

Guanghua Wutong Fund invests primarily in Medical, Health Care and Medical Device startups, most often at Series B and Series A stage. Most of the 14 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Guanghua Wutong Fund?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Guanghua Wutong Fund?

The team at Guanghua Wutong Fund includes Deng Yixin (Vice President) and Xiang Wentian (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co